tbuckley/cabot-search huggingface dataset:
Effectiveness of Universal School-Based Screening vs Targeted Screening for Major Depressive Disorder Among Adolescents
Authors: Deepa L. Sekhar, Krista L. Pattison, Alexandra Confair, Alissa Molinari, Eric W. Schaefer, James G. Waxmonsky, Leslie R. Walker-Harding, Perri Rosen, Jennifer L. Kraschnewski
Journal: JAMA Network Open (2019)

The prevalence of annual major depressive disorder (MDD) episodes among adolescents in the United States rose from 8.3% in 2008 to 12.8% in 2016. Despite the US Preventive Services Task Force 2009 endorsement and 2016 reaffirmation of universal adolescent MDD screening in primary care, many adolescents are missed, as more than 60% lack annual preventive health visits and MDD screening remains inconsistent.To compare the effectiveness of universal school-based screening for adolescent MDD vs the existing process of targeted screening based on observable behavior.Screening in High Schools to Identify, Evaluate, and Lower Depression (SHIELD) is a randomized clinical trial that will take place in at least 8 Pennsylvania public high schools among at least 9650 students enrolled in 9th through 12th grade. Students will be randomized by grade to either targeted screening (current process) or universal screening (intervention). Students in the targeted screening arm will complete mandated school health screenings, which do not include an MDD screening. These students will be observed through the academic year for referral to the Student Assistance Program (SAP), required in all Pennsylvania schools. If a student exhibits behavior concerning for MDD raised by any contact (eg, teacher, parent, peer, or self-referral), SAP will triage the student and provide follow-up recommendations. Students in the universal screening arm will complete the validated Patient Health Questionnaire-9 (PHQ-9) from September through December of the academic year. The PHQ-9 includes 9 close-ended questions and is scored from 0 to 27. Students with a positive result (ie, score >10) will proceed to SAP triage. Students in the intervention arm will also be observed for behavior concerning for MDD during the school year, potentially prompting SAP triage referral. The primary outcome will be the proportion of adolescents referred to SAP triage who are recommended for additional MDD-related services and successfully engage with at least 1 SAP recommendation. Observers will not be blinded to patient groups, and an intention-to-treat analysis will be used.The SHIELD trial began with 3 schools during the 2018-2019 academic year. Screening in the intervention arm with the PHQ-9 is currently underway for the remaining schools, with a goal of completion of all PHQ-9 screenings by December 2019. This trial addresses the US Preventive Services Task Force call for large, high-quality randomized clinical trials to better understand the effects of MDD screening and quantify the proportion of adolescents with screen-detected MDD successfully referred and treated.ClinicalTrials.gov identifier: NCT03716869.
VAV1 Mutations Contributes to the Development of T-Cell Malignancies in Mice
Authors: Kota Fukumoto, Mamiko Sakata-Yanagimoto, Manabu Fujisawa, Tatsuhiro Sakamoto, Tran B. Nguyen, Sakurako Suma, Hiroaki Miyoshi, Koichi Ohshima, Keisuke Kataoka, Seishi Ogawa, Shigeru Chiba
Journal: Blood (2019)
Identification of Targetable Tumor Associated Proteins in Adult T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Including a Novel CC-Chemokine 4 (CCR4)-Positive T-ALL/LBL with Unique Immunophenotype
Authors: Sharad Khurana, Michael G. Heckman, Jordan Cochuyt, Fiona E. Craig, Zaid Abdel Rahman, Patricia Greipp, Lisa Z. Sproat, Mark Litzow, James M. Foran, Liuyan Jiang
Journal: Blood (2019)
Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials
Authors: Max Kates, Andres Matoso, Woonyoung Choi, Alexander S. Baras, Marcus J. Daniels, Kara Lombardo, Aaron Brant, Nina Mikkilineni, David J. McConkey, Ashish M. Kamat, Robert S. Svatek, Sima P. Porten, Joshua J. Meeks, Seth P. Lerner, Colin P. Dinney, Peter C. Black, James M. McKiernan, Chris Anderson, Charles G. Drake, Trinity J. Bivalacqua
Journal: Clinical Cancer Research (2019)

To characterize immune cell expression among patients with non-muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG).Patients with NMIBC treated with intravesical BCG (2008-2015) were identified, and a tissue microarray was constructed using paired pre- and post-BCG bladder samples. Among patients undergoing BCG, cystoscopic evaluation began 3 months after initiating BCG treatment to determine therapeutic response. IHC was performed for CD8, CD4, FoxP3, PD-L1 (SP-142 and 22C3), and PD-1. A full slide review of PD-L1+ staining tumors was performed to characterize PD-L1 and CD8 colocalization. RNA-seq was performed on cored tumors from available specimens. We compared immune cell populations between BCG responders and nonresponders, and between pretreatment and postreatment tumor samples. Baseline PD-L1 staining in the BCG naïve population was then validated in a separate cohort.The final cohort contained 63 pretreatment NMIBC cases, including 31 BCG responders and 32 BCG nonresponders. No differences in CD4, CD8, or FoxP3 expression were identified between responders and nonresponders. Baseline PD-L1 expression (22C3 and SP-142) was observed in 25% to 28% of nonresponders and 0% to 4% of responders (P < 0.01). PD-L1+ cells in BCG nonresponders colocalized with CD8+ T cells. In addition, BCG therapy did not increase PD-L1 gene expression (RNA-seq) or protein levels (IHC). The number of pretreatment CD4+ T cells was very low among PD-L1+ nonresponders (12%) and high among PD-L1- nonresponders (50%, P < 0.01). In a separate cohort of 57 patients with NMIBC undergoing BCG, baseline PD-L1 (22C3) staining was similar (26%).One mechanism of BCG failure may be adaptive immune resistance. Baseline tumor PD-L1 expression predicts an unfavorable response to BCG and if validated, could be used to guide therapeutic decisions.
Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming
Authors: Federico Simonetta, Toshihito Hirai, Juliane K. Lohmeyer, Kristina Maas-Bauer, Maite Alvarez, Arielle S. Wenokur, Jeanette Baker, Amin Aalipour, Samuel Haile, Crystal L. Mackall, Robert S. Negrin
Journal: Blood (2019)
Rupture of the Spleen in Infectious Mononucleosis
Authors: A. R. M. Freeman
Journal: BMJ (1962)

Diagram showing extent of occlusion of the superior mesenteric artery and the site in the ileo-colic artery chosen for anastomosis to the aorta.The inset depicts the completed anastomosis.On regaining consciousness the patient spontaneously said that he had completely lost the constant abdominal pain.Subsequently he was able to eat larger meals than for a year and was entirely free from postprandial pain.His post-operative recovery was uneventful.At the time of writing he remained free of abdominal pain.Cornment.-It is of interest that success was achieved in this case using the ileo-colic artery, a blood-vessel much smaller than vessels found to be of practical value in peripheral vascular surgery.The run-off from the distal vessels rather than the diameter of the vessels probably, however, determines the likelihood of success, and the splanchnic vessels obviously constitute an enormous run-off area. SummnaryA typical case of abdominal angina due to superior mesenteric artery occlusion is described, in which complete relief of the patient's symptoms resulted from direct anastomosis of the ileo-colic artery to the aorta.We thank Mr. D. H. Patey and Dr. H. L. Marriott, under whose care the patient was admitted, for permission to publish this case, and Dr.
Gene Therapy for Lad-I Immunodeficiency: Preclinical Evaluation of HSC Transduction Under Optimized GMP-Conditions
Authors: Elena Almarza, Cristina Mesa-Núñez, Carlos Damián, María Fernández-García, Begoña Díez-Cabezas, M Luz Lozano, Paula Rio, Rosa M Yañez, Ken Law, Brian C Beard, Jonathan D Schwartz, Juan A. Bueren
Journal: Blood (2019)
DRES-06. PROSTAGLANDIN E RECEPTOR 3 MEDIATES RESISTANCE TO TUMOR TREATING FIELDS IN GLIOBLASTOMA CELLS
Authors: Dongjiang Chen, Son Le, Nagheme Thomas, David Tran
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVES Tumor Treating Fields (TTFields) are approved in combination with temozolomide for newly diagnosed glioblastoma (GBM). The addition of TTFields resulted in a significant improvement in overall survival. TTFields are low-intensity alternating electric fields that are thought to disturb mitotic macromolecules’ assembly. However, most GBM patients eventually develop resistance to TTFields. The mechanism of TTFields resistance remains largely unexplored. Understanding how GBM cells circumvent the biophysical forces of TTFields and their downstream effects will improve therapeutic efficacy of this novel anti-cancer treatment modality. METHODS A panel of GBM cell lines were treated continuously with TTFields at the clinically approved frequency of 200 kHz using an in vitro TTFields system until cells with relative resistance to the cytotoxic effects of TTFields. A systems approach aided by innovative network ranking computational algorithms were utilized to analyze global gene expression profiles and identify resistance pathways, which were subsequently validated experimentally. RESULTS TTFields-induced chromosomal instability such as the formation of cytoplasmic micronuclei is preserved in resistant cells, indicating that TTFields resistance is mediated through a non-biophysical mechanism. This acquired TTFields resistance phenotype is associated with a transition of GBM cells to a stem-like state as determined by a neurosphere assay. Using an innovative computational platform, we methodically dissected this stemness program in resistant cells. Mechanistically, Prostaglandin E Receptor 3 (PTGER3) is the top ranked master regulator responsible for resistance. PTGER3 is rapidly upregulated in GBM cells upon exposure to TTFields and further increases with prolonged treatment as resistance sets in. Pharmacological inhibition of PTGER3 either using aspirin to reduce prostaglandin E production or PTGER3-specific inhibitors resensitized cells to TTFields. CONCLUSIONS We have identified a novel pathway with PTGER3 at the apex that plays a critical role in TTFields resistance. This pathway is a potential therapeutic target to reduce resistance to TTFields therapy in GBM.
First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Maja J.A. de Jonge, Benedito A. Carneiro, Lot Devriese, Toshihiko Doi, Sudhir Penugonda, Adam M. Petrich, Silpa Nuthalapati, Monica Motwani, Dimple A. Modi, Yu-Wei Chang, Emiliano Calvo, Victor Moreno
Journal: Blood (2019)
Minimal Residual Disease Monitoring By Next-Generation Sequencing in Patients with Acute Myeloid Leukemia: MRD Positivity after First Consolidation Chemotherapy Can Better Predict Clinical Outcomes Than That after Induction Chemotherapy
Authors: Cheng-Hong Tsai, Jih-Luh Tang, Feng-Ming Tien, Yuan-Yeh Kuo, Chien-Chin Lin, Mei-Hsuan Tseng, Yen-Ling Peng, Ming-Chih Liu, Chia-Wen Liu, Ming Yao, Liang-In Lin, Wen-Chien Chou, Chien-Yu Chen, Hsin-An Hou, Hwei-Fang Tien
Journal: Blood (2019)
Total Penis, Scrotum, and Lower Abdominal Wall Transplantation
Authors: Richard J Redett, Joanna W Etra, Gerald Brandacher, Arthur L Burnett, Sami H Tuffaha, Justin M Sacks, Jaimie T Shores, Trinity J Bivalacqua, Steven Bonawitz, Carisa M Cooney, Devin Coon, Aliaksei Pustavoitau, Nicole A Rizkalla, Annette M Jackson, Vidhi Javia, Samuel A J Fidder, Janice Davis-Sproul, Daniel C Brennan, Inbal B Sander, Shmuel Shoham, Nikolai A Sopko, W P Andrew Lee, Damon S Cooney
Journal: New England Journal of Medicine (2019)

Total Penis, Scrotum, and Lower Abdominal Wall Transplantation This letter describes transplantation of the penis, scrotum, and lower abdominal wall in an injured veteran who had sustained traumati...
Outcomes of Bilateral Cataracts Removed in Infants 1 to 7 Months of Age Using the Toddler Aphakia and Pseudophakia Treatment Study Registry
Authors: Erick D. Bothun, M. Edward Wilson, Deborah K. Vanderveen, David A. Plager, Sharon F. Freedman, Rupal H. Trivedi, Elias I. Traboulsi, Jill S. Anderson, Allison R. Loh, Kimberly G. Yen, Natalie C. Weil, David Morrison, Scott R. Lambert
Journal: Ophthalmology (2019)
Towards a Standardization and Characterization of Clinical Grade Adipose-Derived Stromal Cells
Authors: Chiara Cugno, Rita Calzone, Giusy Gentilcore, Heba Sidahmed, Asma Al-Sulaiti, Moza Al-Khulaifi, Rebecca Mathew, Harshitha Shobha Manjunath, Sara Tomei, Ahmed Makki, Jean-Charles Grivel
Journal: Blood (2019)
Abstract 16719: Vascular Endothelial Growth Factor-C and Mortality in Patients With Stable Coronary Artery Disease and Cancer: A Subanalysis of the ANOX Study
Authors: Moritake Iguchi, Masahiro Suzuki, Morihiro Matsuda, Yoichi Ajiro, Tsuyoshi Shinozaki, Satoru Sakagami, Kazuya Yonezawa, Masatoshi Shimizu, Junichi Funada, Takashi Takenaka, Yukiko Morita, Toshihiro Nakamura, Kazuteru Fujimoto, Hiromi Matsubara, Toru Kato, Takashi Unoki, Daisuke Takagi, Shuichi Ura, Kyoma Wada, Nobutoyo Masunaga, Mitsuru Ishii, Hajime Yamakage, Akira Shimatsu, Kazuhiko Kotani, Noriko Satoh-Asahara, Mitsuru Abe, Masaharu Akao, Koji Hasegawa, Hiromichi Wada
Journal: Circulation (2018)

Background: Recent basic studies suggest the importance of lymphatic vasculature as a therapeutic target in cardiovascular diseases, whereas clinical investigations of vascular endothelial growth factor-C (VEGF-C), a central player in lymphangiogenesis, have focused on its diagnostic possibilities for various malignancies. The expression levels in tumors and/or circulating levels of VEGF-C correlates with lymph node and distant metastasis, and poor prognosis. However, the relationship between VEGF-C and mortality in patients with stable coronary artery disease (CAD) and cancer is unknown. Methods: Serum VEGF-C levels were measured in 133 patients with stable CAD and cancer, enrolled in the development of novel biomarkers related to angiogenesis or oxidative stress to predict cardiovascular events (ANOX) study, and followed up for 3 years. The outcome was all-cause death. Results: During the follow-up, 43 patients (32%) died from any cause (10 patients from cardiovascular cause, and 25 patients from cancer). In Kaplan-Meier analysis, lowest quartile of VEGF-C was significantly associated with all-cause death (hazard ratio [HR], 2.6; 95% confidence interval [CI], 1.4-4.8, but not with cancer-related death (HR, 1.8; 95% CI, 0.8-4.2). After adjustment for established risk factors, low VEGF-C levels and the lowest quartile of VEGF-C were both significantly associated with all-cause death (HR for 1-SD increase, 0.67; 95% CI, 0.47-0.95; HR for values below the 25th percentile, 3.3; 95% CI, 1.7-6.3; respectively). Even after additional adjustment of N-terminal pro-brain natriuretic peptide, contemporary sensitive cardiac troponin-I, and high-sensitivity C-reactive protein, low VEGF-C levels and the lowest quartile of VEGF-C were both significantly associated with all-cause death (HR for 1-SD increase, 0.69; 95% CI, 0.48-0.99; HR for values below the 25th percentile, 2,7; 95% CI, 1.4-5.5; respectively). Conclusions: In patients with stable CAD and cancer, a low VEGF-C value was independently associated with all-cause mortality beyond established risk factors and standard cardiovascular biomarkers. These findings may indicate the difficulty to use elevated VEGF-C as a prognostic marker in patients with cancer.
A Real-Life Study of Autologous Stem-Cell Transplantation in Patients with Multiple Myeloma Older Than 65 Years in a Latin American Country
Authors: Cristian Maximiliano Seehaus, Natalia Paola Schutz, Erika Barbara Brulc, Leandro Burgos Pratx, Gonzalo Ariel Ferini, Jorge A Arbelbide, Dorotea Fantl, Ana Lisa Basquiera
Journal: Blood (2019)
An Alternative to Sodium Polystyrene Sulfonate and Patiromer for the Treatment of Hyperkalemia—Reply
Authors: Deborah Grady, Monica Parks
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Prospective Evaluation of Allogeneic HSCT at the First Remission for Younger Adults with FLT3-ITD Positive Acute Myeloid Leukemia: The JALSG AML209-FLT3-SCT Study
Authors: Naomi Kawashima, Yuichi Ishikawa, Yoshiko Atsuta, Masashi Sawa, Yukiyasu Ozawa, Masaki Hayashi, Akio Kohno, Akihiro Tomita, Tomoya Maeda, Emiko Sakaida, Kensuke Usuki, Maki Hagihara, Heiwa Kanamori, Hiroshi Matsuoka, Miki Kobayashi, Norio Asou, Shigeki Ohtake, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Hitoshi Kiyoi
Journal: Blood (2019)
Prevention of Tuberculosis
Authors: F. Heaf
Journal: BMJ (1956)

It is becoming increasingly apparent that the eradication of tuberculosis depends as much on efficient preventive measures as on the cure of those suffering from the disease.Methods of prevention are changing and will have to change in the future.With increasing success, they will have to be more strictly enforced if a progres- sive decline in the morbidity of the disease is to be main- tained.As the incidence of infected persons declines the search for infectious individuals must be intensified.Complacency and relaxation in the search for active cases and the care of those with a primary infection may result in local epidemics of acute disease in children and young adults, with a possible rise in the morbidity figures for the whole country.There are some who believe that the present decline in mortality is part of a curve with a period of approximately a hundred years.Although the figures have not much statistical value, some evidence for this may be obtained from the tuberculosis mortality curve for the last three hundred years.Little can be said for or against such a hypothesis, but we do know that mortality figures have declined in almost every country in the world and that morbidity figures are beginning to follow in the same way, but at a slower rate.Prevention is not so much concerned with mortality as with incidence, although death removes infectious cases and is in itself a preventive measure.A rapid decline in the number of deaths with a much slower fall in the number of new cases means that there are an increasing number of persons with either active or arrested disease in the country.Whilst this is happening, it means a larger amount of work in the chest clinics in following up the notified cases.From recent surveys we can conclude that there are fewer infectious persons about and that the actual number of tubercle bacilli being disseminated is less in this country than it was a year or more ago.Similar trends may be observed in most European countries, but there are certain places in the world, such as Hong Kong, Bengal, and parts of Nigeria, where the situation is not so favourable.Progress against tuber- culosis has been very erratic throughout the world and many countries are in a worse plight than we were fifty years ago, with 90% infected in the 10-15 age group.On the other hand, in Holland, Scandinavia, and parts of America the infectivity figures are only 2% in the 10-15 age group.This uneven distribution of tuberculous
Use of Anticoagulants of Patients with Cancer-Associated Thrombosis Beyond 6 Months ; The Uscat Study, a 432-Patient Retrospective Non-Interventional Study
Authors: Isabelle Mahe, Ludovic Plaisance, Céline Chapelle, Silvy Laporte, Benjamin Planquette, Laurent Bertoletti, Jean Chidiac, Francis Couturaud, Lionel Falchiero, Nicolas Falvo, Isild Mahé, Hélène Helfer, Guy Meyer
Journal: Blood (2019)
NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival
Authors: Yishai Ofran, Ronit Leiba, Dina Rosenberg, Israel Henig, Dana Yehudai-Ofir, Nuhad Haddad, Riva Fineman, Avraham Frisch, Doaa Okasha, Yariv Carasso, Tsila Zuckerman, Nurit Horesh
Journal: Blood (2019)
QOLP-28. THE USE OF VIRTUAL REALITY FOR SYMPTOM MANAGEMENT: APPLICATION IN NEURO-ONCOLOGY
Authors: Nicole Leggiero, Terri Armstrong, Elizabeth Vera, Mark Gilbert, Amanda King
Journal: Neuro-Oncology (2019)

Abstract Patients with primary central nervous system (CNS) tumors are highly symptomatic due to the functional sequelae of their disease and an unfavorable prognosis. Virtual reality (VR) immersive technology has demonstrated benefit in improving patients’ symptom burden, such as distress, pain, anxiety, and fatigue. However, this has not been explored in a CNS tumor population. This project explored the potential use of VR for symptom management in CNS tumor patients. A descriptive analysis of MDASI-BT/MDASI-SP/PROMIS-Anxiety patient-reported outcomes (PROs) for 535 CNS tumor patients was performed to identify the common moderate-severe (&gt; 4 on a 0–10 scale) symptoms. Additionally, a systematic review of literature was performed addressing the question “For adult patients with solid tumors, what effect does VR have on their self-reported symptoms, such as distress, anxiety and pain?” The systematic literature review resulted in 17 studies using VR in other solid tumor populations, which demonstrated improvement in pain, anxiety, and distress. However, study designs often lacked rigor and none incorporated any biomarkers to correlate with PROs. CNS tumor symptom review of our patient cohort revealed that the majority of the patients were Caucasian (83%) males (58%) with a median age of 50 years (range, 18–83). At the time of diagnosis, 35% had a gross total resection. Glioblastoma was the most common diagnosis (32%) and 50% had a high-grade glioma. The most prevalent moderate-severe symptoms in this sample was fatigue (34%), with (14%) anxiety, (18%) pain, and (19%) distress. Given the high symptom rate in our patients, the promising but limited data that VR technology could improve distress and other symptoms provides strong support for this intervention in the CNS tumor population. Further research is needed to assess feasibility and efficacy of VR, as well as incorporation of correlative biomarkers, to better determine potential improvement in patient symptom burden.
Mice lacking fucosyltransferase 2 show reduced innate allergic inflammation in the airways
Authors: Aiko Saku, Ken‐ichi Suehiro, Kaito Nakamura, Nozomi Nishimura, Masaya Yokota, Koichi Hirose, Hiroshi Nakajima
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.